{"id":15486,"date":"2020-10-17T21:09:37","date_gmt":"2020-10-17T15:39:37","guid":{"rendered":"http:\/\/udaen.info\/?p=15486"},"modified":"2020-10-17T21:09:37","modified_gmt":"2020-10-17T15:39:37","slug":"who-trial-to-assess-other-antibodies-antiviral-drugs-after-remdesivir-doubt","status":"publish","type":"post","link":"https:\/\/udaen.info\/?p=15486","title":{"rendered":"WHO trial to assess other antibodies, antiviral drugs after remdesivir doubt"},"content":{"rendered":"<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-xs-12\">\n<h1 class=\"news_heading detail_title\">WHO trial to assess other antibodies, antiviral drugs after remdesivir doubt<\/h1>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"panel-display panel-1col clearfix\">\n<div class=\"panel-panel panel-col\">\n<div class=\"panel-pane pane-panels-mini pane-news-details\">\n<div id=\"mini-panel-news_details\" class=\"panel-display panel-2col clearfix\">\n<div class=\"panel-panel panel-col-first\">\n<div class=\"inside\">\n<div class=\"panel-pane pane-views pane-news\">\n<div class=\"view view-news view-id-news view-display-id-block view-dom-id-b610ece37a1b3487add9eafa96fc7203\">\n<div class=\"view-content\">\n<div class=\"item-list\">\n<ul>\n<li class=\"views-row views-row-1 views-row-odd views-row-first views-row-last\">\n<div>\n<div class=\"social_share detail_share\">\n<p class=\"date\">17-10-2020 | 11:21 am<\/p>\n<div class=\"social_share_box\"><span class=\"share\">Share Now<img decoding=\"async\" class=\"contrast_light\" src=\"http:\/\/ddnews.gov.in\/sites\/all\/themes\/cmf\/theme\/images\/share.png\" alt=\"\" \/><\/span><\/p>\n<ul class=\"sharebtns\">\n<li class=\"s_icons\"><a class=\"facebook\" title=\"The in%2Finternational%2Fwho-trial-assess-other-antibodies-antiviral-drugs-after-remdesivir-doubt%C2%A0 file Open in new window\" role=\"link\" href=\"https:\/\/www.facebook.com\/sharer.php?u=http%3A%2F%2Fddnews.gov.in%2Finternational%2Fwho-trial-assess-other-antibodies-antiviral-drugs-after-remdesivir-doubt%C2%A0\" target=\"_BLANK\">Share on Facebook<\/a><\/li>\n<li class=\"s_icons\"><a class=\"twitter\" title=\"The in%2Finternational%2Fwho-trial-assess-other-antibodies-antiviral-drugs-after-remdesivir-doubt%C2%A0 file Open in new window\" role=\"link\" href=\"http:\/\/twitter.com\/share?url=http%3A%2F%2Fddnews.gov.in%2Finternational%2Fwho-trial-assess-other-antibodies-antiviral-drugs-after-remdesivir-doubt%C2%A0\" target=\"_BLANK\">Share on Twitter<\/a><\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"views-field views-field-php-1\"><span class=\"field-content\"><img decoding=\"async\" title=\"WHO trial to assess other antibodies, antiviral drugs after remdesivir doubt\u00a0\" src=\"http:\/\/ddnews.gov.in\/sites\/default\/files\/1_264.jpg\" alt=\"WHO trial to assess other antibodies, antiviral drugs after remdesivir doubt\u00a0\" \/><\/span><\/div>\n<div>\n<div class=\"news_content\">\n<p class=\"heading_small\">The World Health Organization said on Friday that it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments after the trial found Gilead Science&#8217;s remdesivir had no impact on survival rates.<\/p>\n<p>WHO Director-General Tedros Adhanom Ghebreyesus said its Solidarity Trial would continue after it was launched in March in 500 hospitals in 30 countries to assess the efficacy of remdesivir and several other drugs in patients with COVID-19.<\/p>\n<p>The Solidarity Trial was at the centre of a dispute on Friday between the WHO and the U.S. company, Gilead, that developed remdesivir.\u00a0 According to Gilead WHO trial&#8217;s findings appeared inconsistent with evidence from other studies.<\/p>\n<p>The WHO&#8217;s trial also found that other medicines repurposed since the pandemic began &#8211; malaria drug hydroxychloroquine, anti-HIV drug combination lopinavir\/ritonavir and interferon &#8211; offered little or no benefit to COVID-19 patients.<\/p>\n<\/div>\n<\/div>\n<\/li>\n<\/ul>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"panel-panel panel-col-last\">\n<div class=\"inside\">\n<div class=\"panel-pane pane-custom pane-1\">\n<div class=\"row pre_next s-pre\">\n<div class=\"col-md-2 col-sm-6 col-xs-6\">\n<div class=\"previous\"><a href=\"http:\/\/ddnews.gov.in\/international\/covid19-updates-across-world\"><img decoding=\"async\" src=\"http:\/\/ddnews.gov.in\/sites\/default\/files\/1_263.jpg\" alt=\"COVID19 updates from across the world\" \/><\/a><\/p>\n<p class=\"previous_title\">COVID19 updates from across the world<\/p>\n<p class=\"previous_link\"><strong>Previous<\/strong><br \/>\nStory<\/p>\n<\/div>\n<\/div>\n<div class=\"col-sm-8 mob_hide\"><\/div>\n<\/div>\n<div class=\"row pre_next s-next\">\n<div class=\"col-md-2 col-sm-6 col-xs-6\">\n<div class=\"next\"><a href=\"http:\/\/ddnews.gov.in\/international\/italy-sets-new-single-day-covid-19-infection-record%C2%A0\"><img decoding=\"async\" src=\"http:\/\/ddnews.gov.in\/sites\/default\/files\/1_265.jpg\" alt=\"Italy sets new single-day COVID-19 infection record\u00a0\" \/><\/a><\/p>\n<p class=\"next_title\">Italy sets new single-day COVID-19 infection record<\/p>\n<p class=\"next_link\">\n<\/div>\n<\/div>\n<div class=\"col-sm-8 mob_hide\"><\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<div class=\"panel-pane pane-views pane-related-articles\">\n<h2 class=\"pane-title pane__title\"><\/h2>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>WHO trial to assess other antibodies, antiviral drugs after remdesivir doubt 17-10-2020 | 11:21 am Share Now Share on Facebook Share on Twitter The World Health Organization said on Friday that it would assess monoclonal antibodies and other antiviral drugs in its trial of potential COVID-19 treatments after the trial found Gilead Science&#8217;s remdesivir had [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"om_disable_all_campaigns":false,"_exactmetrics_skip_tracking":false,"_exactmetrics_sitenote_active":false,"_exactmetrics_sitenote_note":"","_exactmetrics_sitenote_category":0,"_monsterinsights_skip_tracking":false,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"categories":[12],"tags":[],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/15486"}],"collection":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=15486"}],"version-history":[{"count":1,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/15486\/revisions"}],"predecessor-version":[{"id":15487,"href":"https:\/\/udaen.info\/index.php?rest_route=\/wp\/v2\/posts\/15486\/revisions\/15487"}],"wp:attachment":[{"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=15486"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=15486"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/udaen.info\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=15486"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}